Pathcare Labs Pvt. Ltd.
PATHCARE LABS PVT LTD. Regional Laboratory - Plot
No.526, Phase-5, Udyog Vihar, Gurugram-122016,
ICMR No. : PCPLGH (Covid-19)
Ph:- 04061216123
Patient Name : Mrs. FATIMA Reg. No. : 01582501120015
Age and Sex : 23 Yrs / Female PCC Code : PCL-UP-686
Referring Doctor : Dr. DR.NIVEDITA SINHA Sample Drawn Date : 12-Jan-2025 11:10 AM
Referring Customer : N/A Registration Date : 12-Jan-2025 05:12 PM
Vial ID : R2777451 Report Date : 12-Jan-2025 09:30 PM
Sample Type : Serum Report Status : Final Report
Client Address : Shop No: Ug-06,Trident Superior , Trident Embassy, Greater Noida West
CLINICAL BIOCHEMISTRY
Test Name Obtained Value Units Bio. Ref. Intervals Method
(Age/Gender specific)
PDF Attached
Dual Marker - Prisca
Free -Beta -HCG 9.84 ng/mL < 2 :Non-Pregnant CLIA
5.4 - 393.4 : Pregnant
PAPP-A 5.43 mIU/mL < 0.1 : Non-Pregnant CLIA
0.1-19.5 : Pregnant
Test Interpretation Screen-Negative
Comments:-
The first trimester screening programme offers a noninvasive option for the early detection of aneuploidy pregnancies. This screening is done by a combination of two biochemical
markers i.e. serum free β-human chorionic gonadotrophin (free β-hCG) and pregnancy associated plasma protein A (PAPP-A), maternal age and fetal nuchal translucency (NT)
thickness . A beneficial consequence of screening is the early diagnosis of trisomies 21, 18 and 13. All three trisomies are associated with increased maternal age, increased fetal
NT and decreased PAPP-A, but in trisomy 21 serum free β-hCG is increased whereas in trisomies 18 and 13 free β-hCG is decreased
Correlate Clinically. Result rechecked and verified for abnormal cases.
*** End Of Report ***
Page 1 of 1
Note: If the test results are alarming or unexpected,Client is advised to contact the laboratory immediately for possible remedial action.
Pathcare Labs Pvt Ltd
Prisca 5.2.0.13
Date of report: 12/01/25
DR
NIVEDITA SINHA
Patient data
Name Mrs. FATIMA Patient ID 01582501120015
Birthday 11/11/00 Sample ID R2777451
Age at delivery 24.7 Sample Date 12/01/25
Gestational age 12 + 6
Correction factors
Fetuses 1 IVF no Previous trisomy 21 unknown
Weight 51 diabetes no pregnancies
Smoker no Origin Asian
Biochemical data Ultrasound data
Parameter Value Corr. MoM Gestational age 12 + 4
PAPP-A 5.43 mIU/ml 1.04 Method CRL Robinson
fb-hCG 9.84 ng/ml 0.25 Scan date 10/01/25
Risks at term Crown rump length in mm 63.4
Age risk 1:1395 Nuchal translucency MoM 0.91
Biochemical T21 risk <1:10000 Nasal bone present
Combined trisomy 21 risk <1:10000 Sonographer NA
Trisomy 13/18 + NT <1:10000 Qualifications in measuring NT MD
Risk Trisomy 21
1:10 The calculated risk for Trisomy 21 (with nuchal
translucency) is below the cut off, which indicates a
low risk.
After the result of the Trisomy 21 test (with NT) it is
expected that among more than 10000 women with the
same data, there is one woman with a trisomy 21
1:100 pregnancy.
The free beta HCG level is low.
1:250 Cut off The calculated risk by PRISCA depends on the accuracy
of the information provided by the referring physician.
Please note that risk calculations are statistical
approaches and have no diagnostic value!
1:1000
The patient combined risk presumes the NT
measurement was done according to accepted guidelines
(Prenat Diagn 18: 511-523 (1998)).
1:10000
The laboratory can not be hold responsible for their
1315 1719 212325 2729 313335 3739 414345 4749 impact on the risk assessment ! Calculated risks have no
Age diagnostic value!
Trisomy 13/18 + NT
The calculated risk for trisomy 13/18 (with nuchal
translucency) is < 1:10000, which represents a low
risk.
Sign of Physician
below cut off Below Cut Off, but above Age Risk above cut off
